CRISPR Therapeutics Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Public

  • Employees
  • 480

Employees

  • Stock Symbol
  • CRSP

Stock Symbol

  • Investments
  • 8

  • Share Price
  • $38.93
  • (As of Thursday Closing)

CRISPR Therapeutics General Information

Description

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Contact Information

Formerly Known As
Inception Genomics
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Baarerstrasse 14
  • V8
  • 6300 Zug
  • Switzerland
+41 041
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • Baarerstrasse 14
  • V8
  • 6300 Zug
  • Switzerland
+41 041

CRISPR Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CRISPR Therapeutics Stock Performance

As of 19-Nov-2026, CRISPR Therapeutics’s stock price is $38.93. Its current market cap is $3.78B with 97M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$38.93 $40.19 $38.37 - $63.45 $3.78B 97M 1.73M -$4.75

CRISPR Therapeutics Financials Summary

As of 30-Sep-2026, CRISPR Therapeutics has a trailing 12-month revenue of $23.3M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 3,768,434 3,292,858 1,651,413 3,474,231
Revenue 23,323 0 35,000 370,000
EBITDA (435,150) (558,486) (343,406) (130,885)
Net Income (456,135) (581,599) (366,252) (153,610)
Total Assets 2,556,412 2,265,243 2,242,034 2,229,571
Total Debt 779,827 206,746 223,693 238,632
Public Fundamental Data provided by Morningstar, Inc. disclaimer

CRISPR Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore CRISPR Therapeutics‘s full profile, request access.

Request a free trial

CRISPR Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9
Drug Discovery
Zug, Switzerland
480 As of 2025

Cambridge, MA
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

CRISPR Therapeutics Competitors (36)

One of CRISPR Therapeutics’s 36 competitors is Editas Medicine, a Formerly VC-backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Editas Medicine Formerly VC-backed Cambridge, MA
Beam Therapeutics Formerly VC-backed Cambridge, MA
Intellia Therapeutics Formerly VC-backed Cambridge, MA
Genetix Biotherapeutics Private Equity-Backed Somerville, MA
Caribou Biosciences Formerly VC-backed Berkeley, CA
You’re viewing 5 of 36 competitors. Get the full list »

CRISPR Therapeutics Patents

CRISPR Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026210442-A1 Methods and compositions for cellular selection and in vivo tissue enrichment Pending 03-Apr-2025
WO-2026190732-A1 Chemically modified poly(a) tail sequences Pending 12-Mar-2025
WO-2026180998-A1 Pam diversification of cas9 variants Pending 26-Feb-2025
WO-2026180997-A1 Synthetic nucleotide template polymerase (syntase) editing Pending 26-Feb-2025
WO-2026078565-A1 Messenger rna encoding cas9 for use in genome-editing systems Pending 10-Oct-2024 C12N15/85
To view CRISPR Therapeutics’s complete patent history, request access »

CRISPR Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

CRISPR Therapeutics Investments & Acquisitions (8)

CRISPR Therapeutics’s most recent deal was a Later Stage VC with Seawolf Therapeutics for . The deal was made on 16-Nov-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Seawolf Therapeutics 16-Nov-2026 Later Stage VC Drug Discovery
Averna Therapeutics 19-Mar-2026 Early Stage VC Pharmaceuticals
Sirius Therapeutics 22-Sep-2025 Early Stage VC Drug Discovery
ERS Genomics 01-Jan-2022 Merger/Acquisition Biotechnology
Casebia Therapeutics 13-Dec-2019 Merger/Acquisition Drug Discovery
You’re viewing 5 of 8 investments and acquisitions. Get the full list »

CRISPR Therapeutics ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

34.66 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view CRISPR Therapeutics’s complete esg history, request access »

CRISPR Therapeutics Exits (2)

CRISPR Therapeutics’s most recent exit was on 25-Sep-2018 from ViaCyte. The exit was categorized as with 2 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
ViaCyte 25-Sep-2018 Completed
  • 2 buyers
StrideBio 13-Jun-2018 Early Stage VC Completed
  • 6 buyers
To view CRISPR Therapeutics’s complete exits history, request access »

CRISPR Therapeutics Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
ERS Genomics Dublin, Ireland 2014

CRISPR Therapeutics FAQs

  • When was CRISPR Therapeutics founded?

    CRISPR Therapeutics was founded in 2013.

  • Where is CRISPR Therapeutics headquartered?

    CRISPR Therapeutics is headquartered in Zug, Switzerland.

  • What is the size of CRISPR Therapeutics?

    CRISPR Therapeutics has 480 total employees.

  • What industry is CRISPR Therapeutics in?

    CRISPR Therapeutics’s primary industry is Drug Discovery.

  • Is CRISPR Therapeutics a private or public company?

    CRISPR Therapeutics is a Public company.

  • What is CRISPR Therapeutics’s stock symbol?

    The ticker symbol for CRISPR Therapeutics is CRSP.

  • What is the current stock price of CRISPR Therapeutics?

    As of 19-Nov-2026 the stock price of CRISPR Therapeutics is $38.93.

  • What is the current market cap of CRISPR Therapeutics?

    The current market capitalization of CRISPR Therapeutics is $3.78B.

  • What is CRISPR Therapeutics’s current revenue?

    The trailing twelve month revenue for CRISPR Therapeutics is $23.3M.

  • Who are CRISPR Therapeutics’s competitors?

    Editas Medicine, Beam Therapeutics, Intellia Therapeutics, Genetix Biotherapeutics, and Caribou Biosciences are some of the 36 competitors of CRISPR Therapeutics.

  • What is CRISPR Therapeutics’s annual earnings per share (EPS)?

    CRISPR Therapeutics’s EPS for 12 months was -$4.75.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process